BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 21, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Hotspot Therapeutics patents CBL-B inhibitors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
Hotspot Therapeutics patents CBL-B inhibitors
April 30, 2024
No Comments
Hotspot Therapeutics Inc. has identified new E3 ubiquitin-protein ligase CBL-B inhibitors reported to be useful for the treatment of cancer.
BioWorld Science
Cancer
Patents